Lilly Neuroscience International

Channel for the Professional Neuroscience Community. Follow us for congress news, interviews & Alzheimer’s Disease info. Guideline:

[Lilly Neuroscience International @LillyNeuroInt]

Looking toward the future of Alzheimer's disease (AD), Dr. Bonomi explains why it is time to shift how we think about timely diagnosis. Knowing matters more than ever to help patients access support. Watch the video and tell us: What is the biggest change you've seen in AD care?

[Lilly Neuroscience International @LillyNeuroInt]

With the patient in mind, what do you consider the most crucial factor enabled by an early Alzheimer’s disease diagnosis?

[Lilly Neuroscience International @LillyNeuroInt]

What difference can a timely diagnosis make in Alzheimer’s disease? Prof. Marco Bozzali shares 3 reasons why timely identification of Alzheimer’s disease impacts future care. Add your additional reasons for diagnosing early in the comment section.

[Lilly Neuroscience International @LillyNeuroInt]

Early Alzheimer’s disease (AD) detection starts with understanding the cues. Dr. Raphael Wurm outlines 3 signs that help him to differentiate AD from normal aging. What other signs help you differentiate AD from normal aging? How can awareness of these signs be improved?

[Lilly Neuroscience International @LillyNeuroInt]

Happy International Nurses Day! In Alzheimer’s disease patient management, what area holds most potential for nurses to expand impact?

[Lilly Neuroscience International @LillyNeuroInt]

What are the consequences of underdiagnosis in Alzheimer’s disease (AD)? Dr. Atbin Djamshidian shares his thoughts on 3 challenges linked to underdiagnosis in AD, impacting individuals and their families. What are other challenges that you want to share?

[Lilly Neuroscience International @LillyNeuroInt]

What is the most common misconception about Alzheimer’s disease amongst your patients?

[Lilly Neuroscience International @LillyNeuroInt]

At #ADI2026, Lilly engages in the scientific dialogue on the evolving global challenge of Alzheimer’s disease care - reaffirming our commitment to advancing early diagnosis and supporting people living with dementia.
#TimeIsNowAD #EarlyDiagnosis #AlzheimersAwareness

[Lilly Neuroscience International @LillyNeuroInt]

Prevention is a key theme in the Alzheimer’s disease conversation. In this video, Prof. Hisatomo Kowa discusses the importance of integrating prevention strategies into everyday clinical care. Tell us your view in the comments!

[Lilly Neuroscience International @LillyNeuroInt]

Early action matters in Alzheimer’s disease.¹,² At #ADI2026, the community discusses the importance of reducing delays in diagnosis and care. Share your perspective in the comments!
#TimeIsNowAD #EarlyDiagnosis #AlzheimersAwareness

[Lilly Neuroscience International @LillyNeuroInt]

The Alzheimer’s Disease Atlas has launched during #ADI2026! Owned by Alzheimer's Disease International and developed in collaboration with Lilly, this platform hosts country specific data to highlight best practices. Time is Now to turn data to implementation.

[Lilly Neuroscience International @LillyNeuroInt]

One week until the #ADI2026 Global Conference begins. As a Gold Sponsor, Lilly looks forward to supporting conversations across research, care and lived experience in Alzheimer’s disease. What discussions are you most interested in? Let us know in the comments! #TimeIsNowAD

[Lilly Neuroscience International @LillyNeuroInt]

April 7th is World Health Day, and this year’s motto is #StandWithScience. Progress in #AlzheimersDisease relies on rigorous evidence and continuous advancement.¹ Lilly commits to what's next to drive discovery - and the sharing of scientific knowledge brings it into practice.

[Lilly Neuroscience International @LillyNeuroInt]

2 weeks until the #ADI2026 Global Conference kicks off. Researchers, clinicians, advocates, and people living with dementia will exchange perspectives on the future of Alzheimer’s disease care. Which topics do you hope to see highlighted? Tell us in the comments!
#TimeIsNowAD

[Lilly Neuroscience International @LillyNeuroInt]

Timely diagnosis can shape planning, support, and care.¹ Last week at the #ADPD2026, Assoc. Prof. Michael Woodward examined barriers and opportunities in diagnosing Alzheimer’s disease - fueling discussion across research, practice, and #AlzheimersAwareness.

[Lilly Neuroscience International @LillyNeuroInt]

How can we reduce diagnostic uncertainty in Alzheimer’s disease? Last week at the #ADPD2026, Assoc. Prof. Milica G. Kramberger explored this topic, fueling discussions across research, practice, and #AlzheimersAwareness.

[Lilly Neuroscience International @LillyNeuroInt]

Thank you to everyone who contributed to #ADPD2026! The conversations once more underscored how collaboration across disciplines moves Alzheimer’s disease research and care forward. Lilly is proud to have supported this event as a Platinum Plus sponsor. See you next year!
#AlzheimersAwareness #TimeIsNowAD

[Lilly Neuroscience International @LillyNeuroInt]

We’ll be following Dr. Pablo Martinez-Lage at #ADPD2026 as he explores modifiable risk factors in Alzheimer’s disease and the science behind “Protecting the Brain.” These discussions help prevention research and #AlzheimersAwareness move forward.

[Lilly Neuroscience International @LillyNeuroInt]

At #ADPD2026 in Copenhagen, we’re looking forward to hearing from Assoc. Prof. Matteo Pardini. He discusses how using multimodal profiles for neurodegenerative disorders can sharpen studies in the field, supporting #AlzheimersAwareness.

[Lilly Neuroscience International @LillyNeuroInt]

At #ADPD2026, digital biomarkers are increasingly part of the Alzheimer’s disease conversation - from feasibility to validation and clinical relevance.¹ How can digital biomarkers streamline the pathway of Alzheimer’s disease patients? Share your perspective below.